These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24363750)

  • 1. Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.
    Lim KS; Jeong MH; Bae IH; Park DS; Kim JM; Kim JH; Cho DL; Sim DS; Park KH; Hong YJ; Ahn Y
    Korean Circ J; 2013 Nov; 43(11):744-51. PubMed ID: 24363750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model.
    Sim DS; Jeong MH; Park DS; Kim JH; Lim KS; Kim HK; Kim SS; Cho JY; Jeong HC; Park KH; Hong YJ; Kim JH; Ahn Y; Cho JG; Park JC
    Korean Circ J; 2015 Mar; 45(2):110-6. PubMed ID: 25810732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective randomized comparison of clinical and angiographic outcomes between everolimus-eluting vs. zotarolimus-eluting stents for treatment of coronary restenosis in drug-eluting stents: intravascular ultrasound volumetric analysis (RESTENT-ISR trial).
    Hong SJ; Ahn CM; Kim BK; Ko YG; Hur SH; Yu CW; Lee SJ; Choi CU; Kim JS; Yoon JH; Hong YJ; Choi JW; Choi SH; Jang Y; Lim DS;
    Eur Heart J; 2016 Dec; 37(45):3409-3418. PubMed ID: 27634828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR.
    Kim YH; Her AY; Jeong MH; Kim BK; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
    Heart Vessels; 2019 Feb; 34(2):237-250. PubMed ID: 30167772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients.
    Youn YJ; Lee JW; Ahn SG; Lee SH; Yoon J; Park KS; Lee JB; Yoo SY; Lim DS; Cho JH; Choi CU; Jeong MH; Han KR; Cha KS; Lee SY; Choi HH; Choi JW; Hyon MS; Kim MH
    Circ Cardiovasc Interv; 2020 Mar; 13(3):e008525. PubMed ID: 32160779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model.
    Lim KS; Jeong MH; Bae IH; Park JK; Park DS; Kim JM; Kim JH; Kim HS; Kim YS; Jeong HY; Song SJ; Yang EJ; Cho DL; Sim DS; Park KH; Hong YJ; Ahn Y
    J Cardiol; 2014 Nov; 64(5):409-18. PubMed ID: 24852847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of drug eluting stent biocompatibility between third generation NOBORI biolimus A9-eluting stent and second generation XIENCE V everolimus-eluting stent in a porcine coronary artery model.
    Sumida A; Gogas BD; Nagai H; Li J; King SB; Chronos N; Hou D
    Cardiovasc Revasc Med; 2015 Sep; 16(6):351-7. PubMed ID: 26294337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Richardt G; Valgimigli M; Schulz S; Singh A; Abdel-Wahab M; Tiroch K; Pache J; Hausleiter J; Byrne RA; Ott I; Ibrahim T; Fusaro M; Seyfarth M; Laugwitz KL; Massberg S; Kastrati A;
    J Am Coll Cardiol; 2013 Dec; 62(22):2075-82. PubMed ID: 23973699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study.
    Chieffo A; Buchanan GL; Parodi G; Versaci F; Bianchi RM; Valenti R; Saccà S; Mongiardo A; Span S; Migliorini A; Spaccarotella C; Reimers B; Antoniucci D; Indolfi C; Ferrari A; Maehara A; Mintz GS; Colombo A
    EuroIntervention; 2014 Dec; 10(8):916-23. PubMed ID: 24974806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy.
    Masawa T; Abe S; Toyoda S; Sakuma M; Nasuno T; Kageyama M; Tokura M; Koizumi S; Taguchi I; Inoue T
    Heart Vessels; 2016 Aug; 31(8):1230-8. PubMed ID: 26271923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of zotarolimus-eluting stent and everolimus-eluting stent for vascular healing response: serial 3-month and 12-month optical coherence tomography study.
    Kim SJ; Lee H; Cho JM; Park CB; Kim W; Kato K; Yonetsu T; Kim CJ; Jang IK
    Coron Artery Dis; 2013 Aug; 24(5):431-9. PubMed ID: 23722649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of angioscopic findings among second-generation drug-eluting stents.
    Nishimoto Y; Ueda Y; Sugihara R; Murakami A; Ueno K; Takeda Y; Hirata A; Kashiwase K; Higuchi Y; Yasumura Y
    J Cardiol; 2017 Sep; 70(3):297-302. PubMed ID: 28034576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: a randomized Long Drug-Eluting Stent V trial.
    Lee JY; Park DW; Kim YH; Ahn JM; Kim WJ; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Yang TH; Lee BK; Lee NH; Yang JY; Shin WY; Park HS; Kim KS; Hur SH; Lee SY; Park JS; Choi YS; Lee SU; Her SH; Park SJ
    Circ Cardiovasc Interv; 2014 Jun; 7(3):322-9. PubMed ID: 24823426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
    Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Comer Patients Who Underwent Percutaneous Coronary Interventions.
    Pepe M; Biondi-Zoccai G; Corcione N; Nestola PL; Ferraro P; Morello A; Conte S; Prati F; Bianchi FP; Bortone AS; Giordano A
    Am J Cardiol; 2019 Jul; 124(2):195-204. PubMed ID: 31103132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.